Under the deal, the parties plan to pursue development and commercialization of Vibativ in hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP). The company said that additional indications
The Generex proprietary RapidMist drug delivery platform technology administers active pharmaceutical ingredient via aerosolized metered dose spray into the mouth for rapid absorption by the buccal mucosa. The
The companies have agreed to begin feasibility studies to evaluate how selected Novartis’ proprietary biologics can be delivered into the bloodstream using Rani’s unique route of administration. After
This is the first ANDA for a generic version of dolutegravir, less than two years after FDA approval of Tivicay® (dolutegravir) for sale in the United States. Upon
The submission was made under the company’s existing Investigational New Drug (IND) application. The Phase IIb study of ORMD-0801 for type 2 diabetics is designed to generate ample
The company is developing PRX302 (topsalysin) for the treatment of urological diseases. Around 20 patients will be enrolled in this trial, in which previously secured multi-parametric magnetic resonance
The company said that Stiolto Respimat (tiotropium bromide and olodaterol) is not indicated to treat asthma or acute deterioration of COPD, which is a serious but treatable lung
BPD is a field that includes cell engineering, continuous processing, formulation and analytical science, to support development of potential new therapies. The research collaboration will see MedImmune and
Kanuma would be the first approved therapy for these patients if it secures approval from the Ministry. The NDA was based on data from the global, randomized, double-blind,
ZS-9 is an insoluble, non-absorbed zirconium silicate and it has a clearly defined three-dimensional crystalline lattice structure that was designed and engineered to preferentially trap potassium ions. The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.